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Cushing’s disease (CD) is an endocrine disorder originated by a corticotroph tumor. It is 
linked with high mortality and morbidity due to chronic hypercortisolism. Treatment goals 
are to control cortisol excess and achieve long-term remission, therefore, reducing both 
complications and patient’s mortality. First-line of treatment for CD is pituitary’s surgery. 
However, 30% of patients who undergo surgery experience recurrence in long-term 
follow-up. Persistent or recurrent CD demands second-line treatments, such as pituitary 
radiotherapy, adrenal surgery, and/or pharmacological therapy. The latter plays a key role 
in cortisol excess control. Its targets are inhibition of adrenocorticotropic hormone (ACTH) 
production, inhibition of adrenal steroidogenesis, or antagonism of cortisol action at its 
peripheral receptor. Retinoic acid (RA) is a metabolic product of vitamin A (retinol) and 
has been studied for its antiproliferative effects on corticotroph tumor cells. It has been 
shown that this drug regulates the expression of pro-opiomelanocortin (POMC), ACTH 
secretion, and tumor growth in corticotroph tumor mouse cell lines and in the nude mice 
experimental model, via inhibition of POMC transcription. It has been shown to result in 
tumor reduction, normalization of cortisol levels and clinical improvement in dogs treated 
with RA for 6 months. The orphan nuclear receptor COUP-TFI is expressed in normal 
corticotroph cells, but not in corticotroph tumoral cells, and inhibits RA pathways. A first 
clinical human study demonstrated clinical and biochemical effectiveness in 5/7 patients 
treated with RA for a period of up to 12 months. In a recent second clinical trial, 25% 
of 16 patients achieved eucortisolemia, and all achieved a cortisol reduction after 6- to 
12-month treatment. The goal of this review is to discuss in the context of the available 
and future pharmacological treatments of CD, RA mechanisms of action on corticotroph 
tumor cells, and future perspectives, focusing on potential clinical implementation.
Keywords: Cushing disease, pharmacological treatment, adrenocorticotropic hormone, retinoic acid, chicken 
ovoalbumin upstream promoter transcription factor
iNTRODUCTiON
Cushing’s disease (CD) is a severe endocrine disorder associated with increased morbidity and 
mortality, caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma (1). 
It is the most common form of endogenous Cushing’s syndrome (CS) (2), and it is the consequence 
of excessive secretion of cortisol from the adrenal glands. ACTH pituitary adenomas are microad-
enoma in more than 90% of cases (3).
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The clinical phenotype involves features related to metabolic 
syndrome (diabetes mellitus, central obesity, hypertension, and 
dyslipidemia), muscle weakness, easy bruising, hirsutism, and 
cognitive disorders. The main cause of death is represented by 
cardiovascular disease (4–6).
First-line of treatment for CD is transsphenoidal surgery, 
aimed to remove the pituitary adenoma. However, success rates 
are variable (reported as 65–90%) depending on the surgeon’s 
expertise (5, 7). Pituitary radiotherapy and bilateral adrenalec-
tomy are usually selected as second-line therapies when hyper-
cortisolism persists; however, they are associated with long-term 
complications (6, 8).
Pharmacological treatment is recommended to control cor-
tisol excess when surgery is contraindicated or non-curative, or 
while waiting for radiotherapy to come into effect (9, 10).
In this review, we will summarize the current state of art of 
pharmacological treatment of CD. We will focus on retinoic acid 
(RA), its molecular mechanism of action in different models of 
CD, its use, and future perspectives.
Pharmacological Therapy of CD
There are three pathophysiological mechanisms that are targeted 
by different treatments: central inhibition of ACTH secretion, 
adrenal-directed inhibition of steroidogenesis, and glucocorti-
coid receptor (GR) blockade (11) (Table 1).
We will also discuss new molecular targets and other medical 
treatment perspectives. The availability of drugs with different 
mechanisms of action expand the therapeutic spectrum and 
allow drug combinations, as will be pointed, thus permitting 
cortisol levels normalization with the lowest rate of adverse 
effects.
Central Inhibition of ACTH Secretion
Corticotroph adenomas frequently express both dopamine 
receptors (DRs) and somatostatin transmembrane receptor 
(SSTR).
Somatostatin Receptor Ligands (SRLs)
Pasireotide (SOM230) is a novel somatostatin analog that binds 
to multiple SSTR with high affinity and has a 40-fold higher 
affinity for SSTR5 than octreotide. SSTR5 is the predominant 
SSTR expressed in corticotroph tumors (7, 26). Octreotide and 
lanreotide have high affinity for SSTR2 and moderate affinity 
for SSTR5. The expression of SSTR2 is reduced by hypercortisolism 
and SRLs acting on SSTR2 are not effective in CD patients (27, 28). 
SSTR5 expression may be less susceptible to the suppressive effect 
of cortisol (29–31).
Pasireotide is currently the only approved treatment for CD 
directed toward the pituitary gland. It was approved in 2012 in 
US and Europe for the treatment of adult CD patients who did 
not achieve remission after surgery or when it has been contrain-
dicated (7, 28, 32). This drug has been shown to suppress both 
ACTH secretion and cell proliferation (11). A multicenter phase 
III study reported an effectiveness of this somatostatin analog in 
the subcutaneous formulation in 15 and 26% of a total of 162 
patients with a dose of 600 and 900 µg/twice daily (12).
Hyperglycemia is the most common adverse effect occurring 
in 73% of the patients (12). Pasireotide-induced hyperglycemia 
is mediated by a reduction of insulin and incretin hormones 
secretion. Blood glucose levels must be monitored during pasire-
otide administration, mainly in patients with previous diabetes 
mellitus or impaired fasting blood glucose (12, 26). Diarrhea, 
nausea, cholelithiasis, headache, and abdominal pain are also 
common adverse events (31, 33). A subsequent phase III trial, 
on eight patients treated in a single center with pasireotide for 
6 months, also indicated significant tumor shrinkage (3).
In a prospective, multicenter trial, pasireotide was given 
alone or in combination with cabergoline (CAB) with or without 
ketoconazole (KCN) (30). Additional medical therapy in com-
bination with pasireotide may be of benefit for those patients in 
whom normalization of cortisol levels are not achieved (12, 30).
In a recent prospective clinical trial, a subset of patients with 
CD treated with pasireotide showed biochemical and clinical 
improvement after 5 years (13). This study suggests that pasire-
otide is an effective drug for the long-term treatment of patients 
with CD, especially when surgery fails or is contraindicated (13).
In the first prospective phase III trial of monthly intra-
muscular long-acting release pasireotide (LAR), pasireotide 
normalized mean urinary free cortisol (UFC) in about 40% of 
150 patients with CD at month 7 and showed a similar safety 
profile than twice-daily subcutaneous pasireotide (14). LAR 
formulation and monthly administration is an efficient option 
in patients with CD persistent or recurrent, although has not yet 
been approved (14).
DR Agonists
Dopamine receptors are widely expressed in normal neuroendo-
crine tissues and pituitary adenomas, around 80% corticotroph 
tumors express dopamine receptor 2 (D2) (34). The DR family 
consists of five receptor subtypes that include D1-like (D1 and 4) 
and D2-like (D2, 3, and 4) receptors (6). In corticotroph adeno-
mas, the suppressive action of the dopamine agonist CAB on 
ACTH secretion in CD patients has a positive correlation with 
the expression of D2 (34).
Abbreviations: α-MSH, melanocyte-stimulating hormone alpha; ACTH, 
adrenocorticotropic hormone; AI, adrenal insufficiency; AP-1, activator protein 
1; BMP-4, bone morphogenetic protein 4; CAB, carbergoline; CAR, constitutively 
active receptor; CD, Cushing’s disease; CDK, cyclin-dependent kinase; COR-003, 
levoketoconazole; COUP-TF, chicken ovoalbumin upstream promoter transcrip-
tion factor; CRBPII, cellular retinol-binding protein type II; CREB, cAMP response 
element-binding; CRH, corticotropin-releasing hormone; CS, Cushing’s syndrome; 
CYP, cytochrome P450; CYP11B1, 11 beta-hydroxylase; D2, dopamine receptor 2; 
DNA, deoxyribonucleic acid; DR, dopamine receptor; EAR-2, V-erbA-related pro-
tein 2; FABP5, fatty acid-binding protein 5; FDA, Food and Drug Administration; 
FXR, farnesol X receptor; GR, glucocorticoid receptor; KCN, ketoconazole; 
LCI699, osilodrostat; LXR, liver X receptor; MAPK, mitogen-activated protein 
kinase; MC2R, melanocortin 2 receptor; MGMT, O6-methylguanine-DNA- 
methyl transferase; MSK1, mitogen- and stress-activated protein kinase 1; NGFIB, 
nerve growth factor inducible B; NOR1, nuclear orphan receptor 1; Nur77, nerve 
growth factor IB; NURR1, Nur77-related receptor 1; OPDD, mitotane; PKA, protein 
kinase A; POMC, pro-opiomelanocortin; PPAR, peroxisome proliferator-activated 
receptor; PTX1, paired-like homeodomain X 1; PXR, pregnane X receptor; RA, reti-
noic acid; RAR, retinoic acid receptor; RARE, retinoic acid response element; ROR, 
RAR-related orphan receptor; RXR, retinoid X receptor; SOM230, pasireotide; 
SRL, somatostatin receptor ligand; SSTR, somatostatin transmembrane receptor; 
TR, thyroid receptor; UFC, urinary free cortisol; VDR, vitamin D receptor.
TAble 1 | Summary of pharmacological therapy and clinical trials of CD.
Human clinical trial effectiveness Side effects Condition
Central inhibition of adrenocorticotropic hormone secretion drugs
Pasireotide Multicenter phase III trial (12) 15 and 26% of 162 patients with a dose of 600  
and 900 μg/twice daily subcutaneous
Hyperglycemia, diarrhea,  
nausea, cholelithiasis,  
headache, abdominal pain
Approved
Phase III trial (3) All patients (8) with significant tumor shrinkage
Prospective clinical trial (13) Biochemical and clinical improvement after 5 years
Prospective phase III trial (14) 40% of 150 patients normalized mean urinary free  
cortisol (UFC) in 7 months with long-acting release 
pasireotide monthly intramuscular
Cabergoline Retrospective, non-randomized 
analysis (15)
Long term: 30% of 30 patients (mean  
dose 2.1 mg/week) and short term: 30–40%  
of 37 patients (mean dose 3.5 mg/week)  
normalized UFC
Mild (transient dizziness  
and nausea)
Off-label
Prospective, single center  
study (16)
No significant UFC reduction in 20 patients  
(mean dose 5 mg/week)
Retrospective, multicenter  
trial (17)
40% of 53 patients normalized UFC
Rosiglitazone In vivo study (18) 30–43% of patients normalized UFC  
(4–16 mg/day)
Hepatotoxicity and  
cardiotoxicity
Out of medical market
Adrenal-directed inhibition of steroidogenesis drugs
Ketoconazole French retrospective  
multicenter study (19)
49.3% of 200 patients achieved normal UFC  
and 25.6% had at least a 50% decrease
Increment in liver enzymes. 
Potential fatal liver injuries and 
possible drug interactions
Off-label, limited use
Metyrapone Retrospective study (20) 43–76% of 164 patients controlled cortisol levels Gastrointestinal adverse  
effects and hypoadrenalism
Off-label, approved in 
the European Union
Mitotane Retrospective analysis (21) 70% of 76 patients normalized UFC Neurological side effects, 
anorexia, hypercholesterolemia, 
gastrointestinal symptoms,  
and abnormal liver function
Glucocorticoid receptor blockade drugs
Mifepristone Multicenter, open-label  
trial (22)
60% of 50 patients improved glycemic  
parameters; 38% reduced diastolic  
blood pressure
Arthralgia, nausea, headache, 
peripheral edema, decreased 
blood potassium, fatigue, and 
endometrial thickening
Approved by Food and 
Drug Administration 
to patients with 
hyperglycemia or type 2 
diabetes mellitus
New molecular target drugs
Osilodrostat Proof-of-concept study (23) 92% of 12 patients normalized UFC at 10 weeks Fatigue, nausea,  
and headachePhase II trial (23) 84 and 79% of patients normalized UFC at 10  
or 22 weeks, respectively
2 Phase III studies Ongoing
Levoketoconazole Phase III single-arm,  
open-label trial
Ongoing
Phase III clinical trial Ongoing
R-roscovitine Phase II clinical trial Ongoing
Retinoic acid
Prospective, multicenter  
study (24)
43% of 7 patients normalized UFC  
(10–80 mg/day for 6–12 months)
Conjunctival irritation,  
headache, arthralgias, nausea
Approved for acne
Prospective trial (25) 25% of 16 patients normalized UFC and salivary  
cortisol (20–80 mg/day for 6–12 months)
Conjunctiva irritation, cheilitis, 
mucositis, nausea, headache, 
arthralgias
Prospective, single-arm,  
open-label clinical trial
Ongoing
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In a retrospective, non-randomized analysis of 30 CD patients 
treated for long term with CAB (mean dose 2.1  mg/week), 
nine patients (30%) showed a complete response after a mean 
of 37 months. Two patients did not respond after 2 and 5 years, 
respectively, but one patient transiently renormalized UFC after 
increase of CAB dosage. Four initial partial responders did not 
sustain a long-term response. Adverse effects were mild and 
included transient dizziness and nausea (15).
A response rate of approximately 30–40% at a high mean 
dose of 3.5 mg/week (0.5–7 mg/week) has been reported in CD 
patients (11, 15, 16, 35). Recent studies combining CAB and 
KCN showed that up to 79% of patients achieved normal levels 
of UFC (35). Unfortunately, since neither drug has been tested 
in controlled clinical trials, both are used as off-label therapy for 
the treatment of CD.
In a prospective single center study (16), 20 patients with 
CD were treated with CAB (median dose 5 mg/week) during a 
6-week period. Prolactin levels were suppressed in all patients 
(demonstrating treatment compliance). Even though it had been 
previously suggested that higher doses of CAB improve hyper-
cortisolism, no significant UFC reductions were observed in this 
trial, thus demonstrating a limited value of the use of CAB for the 
treatment of CD.
In a retrospective multicenter trial, 53 patients with CD 
received CAB as mono therapy and 9 patients received CAB 
complementary to other therapies. UFC normalization was 
observed in 21 of 53 patients who received CAB as monotherapy 
during a 12-month period (responding patients); 4 patients 
were considered partial responders and 28 patients did not 
modify or raise UFC levels. Among the responding patients, 
five developed corticoid insufficiency. CAB was withdrawn 
after 12  months in 28% of the responding patients, due to 
intolerance or escape. Hypercortisolism control was achieved 
in 23% of the overall patients, for 32.5 months. No significant 
differences were observed between baseline UFC levels, but the 
responding group received lower doses of CAB in comparison 
to non-responding patients (1.5 vs. 3.5  mg/week). Adequate 
response and tolerance to CAB was achieved in 20–25% of CD 
patients and basal UFC levels did not adequately predict the 
treatment response (17).
Peroxisome Proliferator-Activated Receptor (PPAR) Gamma 
Ligands
Peroxisome proliferator-activated receptor gamma ligands have 
shown antiproliferative and apoptotic activity in corticotropina 
murine models. In vivo studies using rosiglitazone from 4 to 
16  mg/day in CD patients demonstrated UFC normalization 
between 30 and 43% of treated patients. Due to its hepatotoxicity 
and cardiotoxicity, this drug was taken off the medical market 
(18, 36, 37).
Adrenal-Directed Inhibition of Steroidogenesis
Adrenal steroidogenesis inhibitors are used as a cornerstone 
of medical treatment of CD (38). KCN, mitotane, etomidate, 
metyrapone, aminoglutethimide, and trilostane are drugs that 
inhibit adrenocortical steroidogenesis. Adrenal steroidogenesis 
inhibitors are generally used to control hypercortisolism in the 
short term. These drugs have the disadvantage of not acting 
directly on the pituitary tumor.
Ketoconazole
Ketoconazole, an antifungal substance, is a synthetic derivative 
of imidazole that diminishes adrenal steroidogenesis (400–
1,200 mg). It is one of the most commonly used off-label drug 
in the treatment of CS (39). KCN blocks key cytochrome P450 
(CYP) enzymes that participate in adrenal cortex steroidogen-
esis. In CS patients, it significantly reduces UFC with a 30–80% 
efficacy (28, 39).
In a French retrospective multicenter study, in 200 patients 
with active CD, KCN was administrated as monotherapy. In this 
study, 49.3% of patients achieved normal UFC, 25.6% had at 
least a 50% decrease, and in 25.4% UFC levels were unchanged. 
About half of the patients who received KCN before surgery 
(40 patients, median final dose of 600  mg/day) exhibited an 
improvement in hypokalemia, hypertension, and diabetes. 
Only 13.5 and 2.5% of patients shown mild and major increase 
in liver enzymes, respectively, that disappeared after drug 
withdrawal (19).
In 2013, the Food and Drug Administration (FDA) limited 
its use because of potential fatal liver injuries and possible drug 
interactions (40). However, the European Agency EMA had rec-
ommended a permission of a marketing authorization for KCN 
(HRA Pharma) in the treatment of CS.
Metyrapone
Metyrapone shows potent and selective inhibition of CYP11B1. 
Reductions in aldosterone and UFC were observed following 
metyrapone treatment. Gastrointestinal adverse effects and 
hypoadrenalism have been described. Metyrapone is employed 
clinically as an off label drug for CS treatment (20, 41).
In a retrospective study with 164 CS patients treated with 
metyrapone monotherapy, 43–76% of them managed to control 
cortisol levels. No escape was reported (20). In the European 
Union, it is approved for the treatment of CS (38).
Mitotane (OPDD)
Mitotane, a synthetic derivative of the pesticide dichlorodi-
phenyltrichloroethane (Lysodren®), is mainly used for its adre-
nolytic action in adrenocortical cancer. It has also a slow, but 
potent, inhibitory action on steroid biosynthesis when used at 
lower doses. Adrenal insufficiency (AI) is frequently observed, 
and replacement therapy with hydrocortisone is needed (11). 
After discontinuation of the treatment, around 70% of patients 
achieve normal UFC and about 10% may have sustained remis-
sion (11, 21).
A number of potential side effects have been associated with 
mitotane, including neurological side effects, anorexia, hyper-
cholesterolemia, gastrointestinal symptoms, and abnormal liver 
function (38).
Etomidate
Etomidate blocks multiple steroidogenic enzymes including side-
chain cleavage complex, aldosterone synthase, 17-hydroxylase, 
11 beta-hydroxylase (CYP11B1), and 17–20 lyase enzymes (38).
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Intravenous etomidate is often used in patients with severe 
hypercortisolism who cannot take oral medication (42). This 
drug is indicated in patients who are not immediate surgical 
candidates and for severe manifestations of CS such as hyper-
tension, severe sepsis, or psychotic crises. Its use requires close 
monitoring at intensive care settings, for central nervous system 
depression. Close serum cortisol monitoring is indispensable to 
avoid AI. Etomidate use may be life-saving when all other treat-
ments have failed (43).
Aminoglutethimide
Aminoglutethimide inhibits the conversion of cholesterol to 
pregnenolone (CYP11A1). Although cortisol decrease is gradual, 
some patients require replacement therapy with hydrocortisone. 
This drug has side effects that limit its use, including lethargy, 
sedation, dizziness, blurred vision, gastrointestinal discomfort, 
headache, myalgia, and skin rash (44). Aminoglutethimide is no 
longer used in patients with CD, due to the association with many 
unfavorable side effects (45).
Trilostane
Trilostane blocks steroidogenesis. This drug was effective for the 
treatment of CS in dogs. It did not show the same effectiveness in 
humans with CD (46). Trilostane is associated with major adverse 
effects including diarrhea, nausea, headache, asthenia, abdominal 
pain, paresthesias, and escape phenomenon. This drug is not used 
anymore for the treatment of CD, because of its limited efficacy, 
compared with other drugs (39).
GR Blockade
Glucocorticoid receptor blockade can be used in selected patients, 
but these drugs are associated with pharmacological interactions 
and adverse events related to their mechanism of action such 
as arthralgia, nausea, headache, peripheral edema, decreased 
blood potassium, endometrial thickening, and therefore require 
frequent monitoring. Moreover, they lack a reliable biomarker to 
monitor their efficacy; therefore, its use is limited.
Mifepristone
Mifepristone is a high-affinity non-selective GR antagonist that 
has greater affinity for the GR: 10 times compared with cortisol 
and 4 times compared with dexamethasone. It does not bind to 
the mineralocorticoid receptor (47). Its antagonism results in 
rapidly controlled systemic effects of cortisol excess in CS patients 
(48). Because the negative feedback is lost, leading to an increase 
in ACTH and subsequent cortisol levels, these parameters are 
not useful for monitoring the efficacy of the treatment or disease 
activity (47).
In a multicenter, open-label trial, mifepristone (at dose 300–
1,200 mg daily) was given orally to 50 patients with CD associated 
with type 2 diabetes or hypertension, during a 6-month period. 
This drug showed an improvement of glycemic parameters (60% of 
patients) and diastolic blood pressure reduction (38% of patients) 
(ClinicalTrials.gov NCT00569582). The most common side effects 
are arthralgia, nausea, headache, peripheral edema, decreased 
blood potassium, fatigue, and endometrial thickening (22). The 
FDA approved mifepristone in 2012 and the specific indication is 
hyperglycemia or type 2 diabetes mellitus due to CS (22).
New Molecular Targets for CD in Clinical Trials
Osilodrostat (LCI 699)
Osilodrostat is an oral inhibitor of CYP11B1 that inhibits 
deoxycortisol hydroxylation to produce cortisol, the final step of 
its synthesis. The mechanism of action of this drug is similar to 
metyrapone (28).
In a 10-week, proof-of-concept study, this drug showed effi-
cacy to normalize UFC in 11 of 12 patients with CD. It produces a 
rise in ACTH, 11-deoxycortisol, and 11-deoxycorticosterone that 
declined after discontinuation. Osilodrostat was generally well 
tolerated. Fatigue, nausea, and headache were the most frequent 
adverse events reported (23).
In a 22-week phase II trial in CD patients, 84 and 79% 
reached UFC normalization at 10 and 22  weeks, respectively 
(49). Plasma aldosterone and cortisol levels decreased in both 
studies, while an increase in the levels of their precursors was 
observed (23, 49).
Osilodrostat use as alternative treatment for CD is promising 
and two phase III studies are currently ongoing (50).
Levoketoconazole (COR-003)
Levoketoconazole is a drug in investigation for CS that acts 
similar to its enantiomer, KCN, but it is hypothesized to provide 
better efficacy and safety (50).
In vitro and in  vivo studies showed that levoketoconazole 
might cause diarrhea, fatigue, dizziness, and abdominal pain. 
It might not be as damaging to the liver as KCN. Levoketoconazole 
could be used to treat endogenous CS of any cause in adult 
patients who are unwilling to have surgery, before surgery, or 
in whom surgery has failed, or while waiting for the effects of 
radiotherapy to occur. A phase III single-arm, open-label trial 
is currently ongoing to determine efficacy, safety, tolerability, 
and pharmacokinetics in CS patients (51). A phase III clinical 
trial to assess the safety and efficacy of levoketoconazole in the 
treatment of endogenous CS is being carried out (ClinicalTrials.
gov Identifier: NCT03277690).
R-Roscovitine
R-roscovitine is a cyclin-dependent kinase (CDK) and cyclin 
E inhibitor that may be a potential therapeutic option for 
CD patients. R-roscovitine was first tested in a mouse model 
showing reduction of serum corticosterone and ACTH levels. 
R-roscovitine suppressed in vitro and in vivo ACTH expression, 
induced senescence and cell cycle exit in corticotroph tumor cells 
by overexpression of p27, p21, and p57, and downregulated cyclin 
E expression (52, 53). A phase II clinical trial in CD patients is 
ongoing.
Other Medical Prospective Treatments
Epidermal Growth Factor Receptor (EGFR)
Epidermal growth factor receptor family is considered a puta-
tive therapeutic target for CD. In murine studies, gefitinib (an 
inhibitor of EGFR tyrosine kinase activity) reduced tumor size 
and corticosterone levels, and reversed hypercortisolemia signs. 
EGFR signaling inhibition may be a novel strategy to treat CD, 
but further studies are needed (54, 55). A clinical trial is ongoing 
(ClinicalTrials.gov Identifier: NCT02484755).
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Selective, Peptide Melanocortin 2 Receptor (MC2R) Antagonists
Adrenocorticotropic hormone acts on MC2R at the adrenal 
cortex and produces chronically increased circulating cortisol. 
A decrease in cortisol levels and adrenocortical androgen 
secretion (preserving mineralocorticoid hormone secretion) 
may be expected when the MC2R activation by ACTH is 
blocked. MC2R could therefore be a new target for the treat-
ment of CD (56).
Chimeric Compounds
Chimeric compounds that bind to both D2R and SSTRs may act 
in synergy, with greater potency than each individual compound, 
to control ACTH release and tumor growth. SST/DA chimeras 
have the ability to interact with both receptors and present 
enhanced potency and efficacy than individual SSTR or DR 
agonists. Currently, second-generation chimeric compounds are 
under development (57). A recent study showed that the chi-
meric compound sst2/sst5/D2 (BIM-23A760) that acts through 
different molecular mechanisms, such as reduction of calcium 
concentration and inhibition of hormonal secretion on pituitary 
adenoma cells, represents a promising therapeutic tool (58).
Temozolomide Monotherapy and in Combination
Temozolomide is an oral alkylating chemotherapy agent, which 
is usually used for the treatment of high-grade astrocytoma, 
glioblastoma, and melanoma. This drug has shown promise as 
monotherapy and in combination with pasireotide, as a treatment 
for aggressive pituitary adenomas and carcinomas (7, 59).
Temozolomide causes deoxyribonucleic acid (DNA) damage 
because it depletes the DNA repair enzyme, O6-methylguanine-
DNA-methyl transferase (MGMT), which results in tumor cell 
apoptosis. MGMT expression levels emerge as inversely related 
to therapeutic response to temozolomide. It has been used as 
a predictor of temozolomide effectiveness (60, 61). For aggres-
sive corticotroph adenomas refractory to surgery, radiotherapy, 
or other medical treatment, temozolomide may represent an 
option (7).
Doxazosin
The selective alpha (1)-blocker doxazosin has shown inhibition of 
pituitary tumor cell proliferation in murine and human models 
and a decrease in plasma ACTH levels. There is not enough 
experience with this drug and further studies are needed (62).
MicroRNAs
MicroRNAs are small non-coding RNA molecules that regulate 
gene expression at the post-transcriptional level. MicroRNAs 
control different processes such us cell differentiation, cell 
growth, and apoptosis. Tumoral corticotroph cell proliferation 
may be limited through microRNAs genetic manipulation. 
It could therefore be a new treatment for CD, but future studies 
are necessary (63).
Monoclonal Antibodies
Bevacizumab, a monoclonal antibody, blocks the expression 
of vascular endothelial growth factor receptor 2. This receptor 
is overexpressed in aggressive pituitary tumors. Bevacizumab 
could be a novel target in the treatment of CD, decreasing cell 
proliferation in aggressive and fast-growing corticotroph tumors 
(64). Antiangiogenic therapy may be promising for the treatment 
of aggressive corticotroph tumors.
Rapamicin
The mTOR complex, a serine–threonine kinase, plays a key role 
in the cell growth, regulation, and proliferation. Rapamicin 
inhibits mTOR pathway and is a potential drug for the treatment 
of CD (65).
Testicular Orphan Nuclear Receptor 4 (TR4)
Overexpression of TR4 promotes corticotroph cell proliferation, 
ACTH secretion, and pro-opiomelanocortin (POMC) transcrip-
tion. It could be another potential target to achieve control of 
hypercortisolism in patients with CD (66).
Retinoic Acid
Retinoic acid is a product of the metabolism of vitamin A/retinol, 
whose most used derivative is its cis isomer called Isotretinoin.
For many years, retinoids have been applied to therapeutically 
treat skin diseases, mainly acne. As a consequence of increasing 
understanding of their molecular action, their uses were diversi-
fied, involving their application in oncology and non-cancer-
related applications (premalignant conditions and diseases such 
as chronic obstructive pulmonary, Alzheimer, and Parkinson) 
(67). Some groups have reported antitumorigenic effects for 
retinoids in several malignant diseases: epithelial tumors (68), 
cutaneous malignant diseases (69, 70), Kaposi’s sarcoma (71, 72), 
squamous cell carcinomas (73, 74), cutaneous T-cell lymphoma 
(75, 76), neuroblastoma (77), lung cancer (78), acute promyelo-
cytic leukemia (79, 80), and others. In addition, immune stimu-
lating effects of RA have been described (81).
There is evidence that retinoids participate in pituitary 
development (82) and adult pituitary gland has retinoid recep-
tors, specific genes with retinoic acid response element (RARE) 
sequence and enzymes of the metabolism of retinoids (83–86).
Mechanism of Action of RA
The classical mechanism of RA action involves a nuclear hor mone 
receptor-mediated activation of the transcriptional machinery 
on target genes, as well as activation of kinase cascades. This 
ability to activate multiple transcriptional and non-genomic 
programs gives RA enormous therapeutic potential.
Once in the target tissue, RA is delivered to its nuclear 
receptor through intracellular binding proteins such as cellular 
retinol-binding protein type II and fatty acid-binding protein 
5 (87). RA interacts with two classes of receptors, RA receptor 
(RAR) (88) or retinoid X receptor (RXR) (89), each of which has 
three isoforms (α, β, and γ) (Figure 1). Both receptors belong 
to the steroid hormone/nuclear receptor superfamily along 
with estrogen, thyroid hormone, vitamin D, and orphan recep-
tors (90). RARs and RXRs heterodimers act as RA ligands, but 
RXRs can heterodimerize with other nuclear receptors [vitamin 
D receptor, PPAR, liver X receptor, thyroid receptor, pregnane 
X receptor, RAR-related orphan receptor, farnesol X receptor 
(FXR), chicken ovoalbumin upstream promoter transcription 
FiGURe 1 | Mechanism of action of RA receptors (RARs). Retinoic acid  
(RA) nuclear receptor RARs and retinoid X receptors (RXRs) heterodimerize  
in the presence of the ligand that binds to RAR. The complex interacts with 
deoxyribonucleic acid containing specific RA responding element sequences 
[retinoic acid response element (RARE)], to mediate gene transcription. 
Chicken ovoalbumin upstream promoter transcription factor (COUP-TF)  
[as others nuclear receptors such as known ligand receptors vitamin D 
receptor (VDR), peroxisome proliferator-activated receptor (PPAR), liver X 
receptor (LXR), thyroid receptor, pregnane X receptor (PXR), RAR-related 
orphan receptor (ROR), and farnesol X receptor (FXR), or orphan receptors 
BGFIB, Nur77-related receptor 1 (NURR1), nuclear orphan receptor 1 
(NOR-1), V-erbA-related protein 2 (EAR-2), and CAR] is able to dimerize  
with RXR. The complex with COUP-TF inhibits the effect of RA. Depending 
on the co-factors that are recognized by RAR-RXR complex, transcription  
of the target gene is activated or inhibited.
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factor (COUP-TF), nerve growth factor inducible B, Nur77-
related receptor 1 (NURR1), nuclear orphan receptor 1, V-erbA-
related protein 2, and constitutively active receptor (CAR)] (91) 
that act as rexinoid ligands. These nuclear receptors can activate 
transcription through the RA response elements RAREs in the 
target genes or assemble into co-repressor complexes for other 
gene pathways (92). The large number of possible complexes 
brings a very high degree of plasticity (93, 94). Moreover, RAR/
RXRs contain several phosphorylation sites modified by kinases 
such as protein kinase A, mitogen- and stress-activated protein 
kinase 1, CDKs, and mitogen-activated protein kinases, which 
further makes the response more complex. An additional level 
of complexity is the fact that the magnitude and duration of the 
response is regulated through RARs and RXRs degradation by 
the proteasome.
Chicken ovalbumin upstream promoter transcription fac-
tors belong to the superfamily of the steroid/thyroid hormone/
vitamin receptors (95). COUP-TFs are supposed to have an 
important evolutionary and functional role given the high 
conservation of their amino acid sequence between species 
(96). COUP-TFs are orphan receptors because no endogenous 
ligands have been identified so far. COUP-TFI is more highly 
expressed in neuronal tissues of the central and peripheral 
nervous systems, whereas COUP-TFII is mainly present in 
developing organs (97–100).
Chicken ovoalbumin upstream promoter transcription factors 
are negative regulators of RA signaling (101–103). It has been 
reported that during development the signaling of COUP-TFs 
and retinoids have a functional crosstalk evidenced by the 
antagonistic action of COUP-TF on retinoid target genes and 
the fact that RA can modulate COUP-TFs expression (104, 105). 
In fact, COUP factors are considered as part of the RA signal-
ing pathway (104–108). Besides, COUP-TFI, RARα, and RARβ 
knockout mice share common phenotypes (109–111).
RA in Corticotroph and Other Cellular Models
In AtT-20 pituitary ACTH-secreting tumor cells, an experi-
mental cellular model of corticotroph adenomas, RA inhibits 
POMC transcription and stimulation of POMC by corticotro-
pin-releasing hormone (CRH), being these effects highly spe-
cific because RA does not affect key factors of the corticotroph 
function such as cAMP response element-binding, GR, and 
paired-like homeodomain X 1 (112). In contrast to the action 
of RA showing POMC transcriptional inhibition, a synthetic 
agonist that acts only on RARα, Am80, has been described 
to increase POMC mRNA expression, CRH-induced ACTH 
secretion, and POMC promoter activity in AtT-20 corticotroph 
cells (113).
As part of its antitumorigenic action, RA inhibits ACTH and 
corticosterone-secreting cells proliferation. These antiprolife-
rative effects involve transcription factors such as activator pro-
tein 1 and Nur77/Nurr1 (112). RA induces bone morphogenetic 
protein 4 (BMP-4), which participates in its antiproliferative 
effects (114) and has been also shown to be involved in the 
action of somatostatin analogs on corticotrophs (115). In GH3 
and AtT-20 cells, RA-induced expression of BMP-4 involves 
chromatin remodeling (116). On the other hand, RA induces 
apoptosis/cell death in ACTH-secreting cells by inducing cas-
pase-3 activity (112).
Furthermore, RA inhibits ACTH production in primary cul-
ture of human corticotrophins (112). In accordance, RA reduces 
ACTH endogenous production in tumor cells although it has no 
effect on non-tumoral pituitary cells (112) (Figure 2). In primary 
cultures from 10 human adrenal specimens, RA blunted ACTH 
receptor transcription (117).
RA in Rodent and Canine Models
In RA-treated AtT-20 xenographed nude mice, an in vivo model 
of corticotropina, RA reduces tumor mass and reverses endo-
crine alterations (112). RA also decreases plasma ACTH and 
cortisol, together with a reduction in adrenal hyperplasia and 
skin atrophy in these rodents (112).
Cushing’s disease is a common disorder in dogs (118). A dose 
of 2 mg/kg body weight/day of RA results effective and safe in 
this model (119). This treatment with RA reduces plasma ACTH 
and melanocyte-stimulating hormone alpha and diminishes 
the cortisol/creatinine urine ratio, leading to normalization of 
the gonadal axis and the estrous cycle (119). After a period of 
180 days of treatment, RA reduced pituitary adenoma size, while 
survival time and clinical signs (food intake, skin appearance, and 
hair recovery) improved (119). RA action has not adverse events 
neither hepatotoxicity in dogs (119) (Figure 2).
FiGURe 2 | Effects of retinoic acid (RA) on different experimental models of Cushing disease. Blue arrows: hormones/factors/read-outs than decrease  
with RA administration; fuchsia arrows: hormones/factors/read-outs than increase/improve with RA administration.
8
Fuertes et al. CD Treatments and RA
Frontiers in Endocrinology | www.frontiersin.org May 2018 | Volume 9 | Article 262
Besides, in a poodle dog with Nelson’s syndrome with iatro-
genic hypoadrenocorticism induced by mitotane, RA reduced 
plasma ACTH and macroadenoma size after 10 months of treat-
ment (2 mg/kg/day) (120).
RA in Humans
In the first study in seven patients with CD, in five patients 
UFC levels decreased markedly after RA administration for 
6–12 months (doses of 10–80 mg/day) and three of them reached 
normalization (24). The levels of plasma ACTH did not show a 
modification at the end of the treatment in responsive patients, 
while other signs showed an improvement (blood pressure, 
glycemia, and sings of hypercortisolism). Adverse events were 
mild and transient, including conjunctive irritation, headache, 
arthralgia, and nausea. Three patients complained of mild 
arthralgias, another three of xerophthalmia, two of abdominal 
pain, and one patient reported headaches. There were no reports 
of hepatic or renal dysfunction. One of the responding patient 
maintained normal UFC levels after isotretinoin withdrawal. 
This would be explained by a prolonged inhibitory effect of RA 
on corticotroph tumor cells (24).
In a recently prospective trial, isotretinoin was given orally 
for 6–12 months to 16 patients with persistent or recurrent CD 
in a dose ranging from 20 to 80 mg/day. Before drug administra-
tion and every month, clinical/biochemical data were registered. 
An initial response with normalization of the UFC and salivary 
cortisol was observed in six patients (37.5%). Subsequently, 
two patients escaped or relapsed. The group of responding 
patients had significantly lower mean age and lower mean 
basal levels of UFC, nocturnal salivary cortisol, and ACTH, in 
comparison with non-responders patients. Only patients who 
had UFC levels <2.5-fold ULN obtained UFC normalization. 
In a non-responding patient treated with a full-tolerated dose of 
CAB (3 mg/week), UFC levels were normalized after the addi-
tion of isotretinoin 50  mg/day. This combination allowed the 
reduction of CAB dose to 2 mg/day and hence the optimization 
of the tolerance profile. At the end of the study, four patients 
(25%) achieved the normalization of UFC levels. In the rest of 
the patients, UFC levels experienced up to 52.1% reduction. 
Isotretinoin side effects were experienced by seven patients 
(conjunctiva irritation, cheilitis, mucositis, nausea, headache, 
and arthralgias), though they were mostly transient. The authors 
of this study conclude that RA could be useful in patients with 
mild hypercortisolism (25).
The FDA approved RA for acne treatment in 1982. The usual 
dose for the treatment of acne vulgaris is 0.5–1  mg/kg/day. 
In patients with CD, in previous clinical trials, the initial dose 
was 20 mg/day and the maximum dose was 80 mg/day.
The described mild adverse effects for acne treatment include 
skin and annexes disorders, xerophthalmia, dry skin, conjunctiva 
irritation, dermatitis, pruritus, rash, hair fragility, and alopecia. 
Musculoskeletal system disorders: pain in muscle and joints, 
arthritis. Sensory disorders: photophobia, lenticular cataract, 
and keratitis. Gastrointestinal system disorders: nausea, intestinal 
inflammatory diseases such as colitis, ileitis, and hemorrhages. 
Laboratory findings: transaminases elevation (reversible and 
transient), increase in serum triglycerides and cholesterol, 
hyperuricemia. Although a causal relationship has not been 
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established, high fasting blood sugar levels have been reported, 
and new cases of diabetes have been diagnosed during therapy. 
Serious adverse effects included psychiatric disorders, rash, 
metabolic disorders, increased intracranial pressure, renal, and 
abdominal disturbances. RA is contraindicated in patients with 
renal or hepatic insufficiency.
Retinoic acid is highly teratogenic; therefore, it is contraindi-
cated not only in pregnant women but also in women of child-
bearing age. The latter group could only use RA in combination 
with two contraception methods (121).
In the two studies on patients with CD, RA has shown good 
response pattern in patients with mild hypercortisolism. It was 
generally well tolerated with transient and mild adverse effects 
(arthritis, xerophthalmia, nausea, and headache) (24, 25). This 
would represent an advantage, over other drugs such as pasire-
otide (worsening diabetes symptoms), KCN (hepatotoxicity), 
and mifepristone (arthralgia, peripheral edema, decreased blood 
potassium, fatigue, and endometrial thickening).
FUTURe PeRSPeCTiveS
In primary culture of human corticotrophins, normal ACTH-
secreting cells express COUP-TFI, but tumoral cells do not (112). 
Corticotroph normal cells do not respond to RA treatment and 
this may be attributed to the fact that they express the inhibi-
tory factor COUP-TFI. In fact, when tumoral cells responding 
to RA are transfected with a COUP-TFI expression vector, the 
response to RA is abolished (112). In 34 specimens of human 
pituitary adenomas, 29 expressed COUP-TFI but only 5 of them 
presented expression of COUP (122). This interesting difference 
between normal/tumoral COUP-TFI expression makes this 
protein a promising biomarker of a possible response of the cells 
to RA action. In lung cancer, the antiproliferative action of RA 
depends on Nur77/COUP-TFI balance (123). Currently, there 
are no long-term studies involving RA. An ongoing controlled 
clinical trial in which both, the long-term efficacy of RA and the 
correlation with the expression of COUP-TFI are tested, would 
contribute to clarify the future perspective to implement RA as a 
potential drug for CD treatment.
CONClUSiON
Cushing’s disease presents high morbidity and mortality in the 
absence of proper treatment.
Although transsphenoidal surgery is the primary option, some 
patients are not candidates to surgery, or do not achieve remission 
after long-term control.
New knowledge about the mechanisms involved in the 
pathophysiology of CD led to the discovery of new targets for 
developing drugs that seek to reduce the secretion of ACTH. 
Targeting specific molecules, and searching biomarkers which 
predict response to different drugs, is the path to accomplish 
effective treatment. RA represents a new alternative to medical 
treatment in CD, but the true efficacy should be assessed in long-
term controlled studies.
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